Ultragenyx Pharmaceutical Inc (NAS:RARE)
$ 42.61 1.49 (3.62%) Market Cap: 3.54 Bil Enterprise Value: 3.05 Bil PE Ratio: 0 PB Ratio: 24.36 GF Score: 70/100

Ultragenyx Pharmaceutical Inc at Bank of America Healthcare Conference Transcript

May 10, 2022 / 09:40PM GMT
Release Date Price: $53.56 (+3.40%)
Tazeen Ahmad
BofA Securities, Research Division - MD in Equity Research & Research Analyst

Hi, everybody, good afternoon, and once again welcome back to the Bank of America Healthcare Conference. I'm Tazeen Ahmad. I'm one of the senior SMID biotech analysts here at the bank. Our next presenting company is Ultragenyx. Sitting with me are 2 really knowledgeable women, Camille and Mardi. I'll let you both introduce yourselves, and then maybe Camille, you can give us -- or Mardi rather, you can give us an overview of the company and then both of you can participate in some more specific Q&A that we have lined up, if that works.

Camille L. Bedrosian
Ultragenyx Pharmaceutical Inc. - Chief Medical Officer & Executive VP

Sounds great. Thank you.

Mardi C. Dier
Ultragenyx Pharmaceutical Inc. - Executive VP & CFO

You want to start?

Camille L. Bedrosian
Ultragenyx Pharmaceutical Inc. - Chief Medical Officer & Executive VP

Okay. Sure. Hi, everyone. I'm Camille

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot